Prilocaine

Specifications

721-50-6CAS Number

211-957-0EC Number

N-(2-methylphenyl)-2-(propylamino)propanamideIUPAC Name

C13H20N2OChemical Formula

220.31 g/molMolecular Weight

prilocaine; 721-50-6; Propitocaine; prilocaine base; N-(2-Methylphenyl)-2-(propylamino)propanamide; Prilocaina; Prilocainum; Astra 1515; Propanamide, N-(2-methylphenyl)-2-(propylamino)-; o-Methyl-2-propylaminopropionanilide; o-Propionotoluidide, 2-(propylamino)-; 2-(Propylamino)-o-propionotoluidide; Astra 1512; o-Methyl-alpha-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide; alpha-n-Propylamino-2-methylpropionanilide; NSC-40027; ASTRA-1512; ASTRA-1515; CHEBI:8404; 046O35D44R; DTXSID7031955; FORTACIN COMPONENT PRILOCAINE; NSC40027; N-(2-methylphenyl)-2-(propylamino)propanimidic acid; RefChem:56655; DTXCID5011955; N01BB04; 211-957-0; Citanest; 2-(Propylamino)-N-(o-tolyl)propanamide; NSC 40027; Propitocaine (JAN); 2-Methyl-.alpha.-propylaminopropionanilide; MFCD00048681; o-Propionotuluidide, 2-propylamino-; Prilocaine [USAN]; N-(2-methylphenyl)-N~2~-propylalaninamide; PROPITOCAINE [JAN]; Prilocainum [INN-Latin]; Prilocaina [INN-Spanish]; (R)-Prilocaine; (S)-Prilocaine; (+/-)-Prilocaine; HSDB 3386; Prilocaine (USP/INN); o-Propionotoluidide, 2-propylamino-; EINECS 211-957-0; BRN 2108498; Prilotekal; Prilocain; Prilocaine CRS; UNII-046O35D44R; Prilocaine [USAN:USP:INN:BAN]; Prilocaine (Standard); N-(o-tolyl)-2-(propylamino)propanamide; Spectrum_001649; PRILOCAINE [MI]; PRILOCAINE [INN]; N-(2-methylphenyl)-N(2)-propylalaninamide; Prestwick0_000199; Prestwick1_000199; Prestwick2_000199; Prestwick3_000199; Spectrum2_001549; Spectrum3_001052; Spectrum4_001192; Spectrum5_001175; (.+/-.)-Prilocaine; PRILOCAINE [HSDB]; PRILOCAINE [VANDF]; PRILOCAINE [MART.]; CHEMBL1194; PRILOCAINE [USP-RS]; PRILOCAINE [WHO-DD]; Lopac0_001005; SCHEMBL25467; BSPBio_000157; BSPBio_002604; KBioGR_001883; KBioSS_002129; DivK1c_000846; SCHEMBL448102; SPBio_001398; SPBio_002078; BPBio1_000173; GTPL7276; orb1300315; orb3141414; DL-(+/-)-PRILOCAINE; EMLA COMPONENT PRILOCAINE; PRILOCAINE [ORANGE BOOK]; SCHEMBL31333079; HY-B0137R; KBio1_000846; KBio2_002129; KBio2_004697; KBio2_007265; KBio3_001824; PRILOCAINE [EP MONOGRAPH]; NINDS_000846; ORAQIX COMPONENT PRILOCAINE; GLXC-05261; HMS3604H09; HMS3651M13; HMS3884A04; HMS5079M20; PRILOCAINE [USP MONOGRAPH]; HY-B0137; MSK15263; PAA28931; PAA28932; BDBM50225477; EBC-11101; s1619; STL257086; AKOS015889404; AC-2100; CCG-205085; CS-1929; DB00750; SDCCGSBI-0050978.P004; IDI1_000846; NCGC00015860-02; NCGC00015860-03; NCGC00015860-15; NCGC00162312-01; AS-14851; FP137966; o-Methyl-.alpha.-propylaminopropionanilide; SY163181; SBI-0050978.P003; DB-055611; AB00053665; NS00000546; SW196783-3; T6953; .alpha.-n-Propyl-amino-2-methylpropionanilide; C07531; D00553; EN300-188120; AB00053665-12; AB00053665_13; AB00053665_14; F468387; N-(2-Methylphenyl)-2-(propylamino)propanamide #; Q413598; Propranamide, N-(2-methylphenyl)-2-(propylamino)-; BRD-A53952395-001-02-4; BRD-A53952395-003-05-3; BRD-A53952395-003-15-2; BRD-A53952395-003-25-1; Z44530398; (+/-)-N-(2-PROPYLAMINOPROPIONYL)-2-TOLUIDINE; N-(2,6-DIMETHYLPHENYL)-2-(PROPYLAMINO)PROPANAMIDESynonyms